QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-initiates-coverage-on-lexeo-therapeutics-with-buy-rating-announces-price-target-of-30

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announc...

 chardan-capital-maintains-buy-on-lexeo-therapeutics-raises-price-target-to-17

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and raises the price target fr...

 lexeo-therapeutics-fda-feedback-opens-faster-path-pivotal-study-for-friedreich-ataxia-gene-therapy-could-shrink-and-speed-up-approval

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

 fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

 hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the pric...

 lexeo-therapeutics-q2-eps-060-beats-068-estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...

 oppenheimer-initiates-coverage-on-lexeo-therapeutics-with-outperform-rating-announces-price-target-of-20

Oppenheimer analyst Leland Gershell initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and anno...

 the-fda-grants-breakthrough-therapy-designation-to-lexeo-therapeutics-lx2006-based-on-clinical-evidence-generated-on-both-cardiac-and-neurologic-measures-of-friedreich-ataxia

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot ...

 1-lexeo-launches-40m-rna-heart-drug-venture-with-backing-from-top-biotech-investors

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

 jp-morgan-maintains-overweight-on-lexeo-therapeutics-lowers-price-target-to-10

JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from...

 hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-15

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION